Tips for Dosage Forms & Drug Delivery Systems

Investigating Phase Separation after a Change in Supplier: A Manufacturing and Laboratory Perspective Phase separation is a critical issue in pharmaceutical manufacturing, particularly when a change in supplier occurs. This…

In a compliant pharmaceutical manufacturing setting, identifying the early signs of viscosity drift is crucial. Symptoms may manifest in various ways:Click to read the full article.

Identifying symptoms related to viscosity drift is crucial for timely intervention. Common signals on the production floor or within the lab may include:Click to read the full article.

Identifying the signs of E&L failures is the first step in determining the underlying issue. Symptoms might include:Click to read the full article.

The initial step in addressing texture grittiness complaints involves identifying symptoms or signals that indicate there may be an underlying problem. Such symptoms may arise from both the production and…

The initial identification of texture grittiness complaints often originates from various sources, including customer feedback, batch release testing failures, or in-process control assessments. Recognizing the symptoms and signals is critical…

The first step in addressing assay OOS during inspection readiness is to identify the symptoms or signals indicating potential quality issues. Below are some common scenarios that may trigger an…

Content uniformity failures can manifest in several ways during manufacturing or during quality control (QC) laboratory testing. Recognizing these symptoms promptly can mitigate potential risks and inform necessary actions. Here…

Identifying symptoms or signals associated with E&L failures is crucial for swift action. Common signs include:Click to read the full article.